According to sources, Indian company Aurobindo wants to pay up to USD 5.5 billion for Zentiva

Indian pharmaceutical company Aurobindo Pharma is negotiating the takeover of Czech drug manufacturer Zentiva. The transaction could be worth up to USD 5.5 billion (more than CZK 115 billion), which would make it the largest acquisition ever made by an Indian pharmaceutical company. The Economic Times reported this today, citing sources familiar with the situation.

Takeover talks

According to sources, Aurobindo is in talks with Zentiva’s current owner, US investment company Advent International. Advent bought Zentiva in 2018 from French pharmaceutical group Sanofi for €1.9 billion (approximately CZK 46.5 billion at the current exchange rate).

Aurobindo said in a statement to the stock exchange that management had not yet signed any binding agreements. Advent International and Zentiva declined to comment on the report, Reuters reported.

Zentiva’s results and operations

Drug manufacturer Zentiva k.s. saw its net profit fall by about a third to CZK 111.6 million in 2023. On the other hand, the company’s total revenue grew by almost a fifth year-on-year to nearly CZK 22 billion. Zentiva focuses on the development, manufacture, and distribution of generic drugs.

The group’s products are intended, for example, for the treatment of pain, cardiovascular diseases, diseases of the central nervous system, digestive, urinary and reproductive systems, and respiratory problems. According to its website, Zentiva operates in 35 countries and employs nearly 4,800 people.

In addition to its Prague headquarters and production plant, the company has other manufacturing and distribution facilities in Europe, from where it supplies key markets. The company has long emphasized the importance of making medicines available to the general public and is also investing in expanding its portfolio to meet growing demand for generic drugs throughout Europe and beyond.

Source: ČTK

author avatar
EditorialTeam
The Trader-Magazine.com EditorialTeam is a collective of certified financial analysts, active traders, and cryptocurrency experts. Our mission is to transform complex market data (forex, equities, indices) into accessible financial education. All content undergoes rigorous, multi-level fact-checking to ensure we deliver only accurate, objective information for your trading and investment decisions.

Top 10 financial instruments for 2022. What will their prospects be in 2023?

The year 2022 has brought countless surprises and obstacles...

Telegram scams: how they work and how to protect yourself

Telegram has become one of the most widely used...

Trump Saved TikTok from a Ban. The App in the U.S. Moves into American Hands

TikTok narrowly avoided a ban in the United States...

Climate Change Poses Major Risks to Financial Markets, Regulator Warns

WASHINGTON — A top financial regulator is opening a...

Golden Brokers Review

Golden Brokers Limited was founded in 2018, it is...

Shares of semiconductor company AMD plunged after a report on its ties to China

Shares of the American company Advanced Micro Devices (AMD),...

Slippage in Trading: Why Your Fill Price Can Differ From the Screen

Slippage in trading occurs when an order executes at...

Buy Limit vs Buy Stop: The Difference Explained on One Price Chart

Two investors want to buy the same stock, currently...

Anthropic Carries Out the Largest Initial Public Offering in History

The initial public offering (IPO) of shares in the...

Gold Falls Despite High Inflation

Gold fell to $3,757 per troy ounce on the...

Global Lack of Control Over Artificial Intelligence Is a Risk, Canadian Prime Minister Says

The lack of global oversight of artificial intelligence (AI)...

Trading Session Times: How Liquidity Changes Through the Global Day

Global financial markets operate across different time zones, but...
spot_img